Oral Bioavailability Enhancement

 

Small Molecules and Peptides

 

Contact us

Leiden, May 15th, 2023: 

SeraNovo and AstraZeneca to collaborate on research projects

SeraNovo (Leiden, The Netherlands) is pleased to announce the closing of a multi compound deal with AstraZeneca (Cambridge, United Kingdom)

 

Read more


The Benefits of our technology 

Bioavailability Enhancement

1.5 – 3-fold higher bioavailability enhancement than competing technologies

Rapid Formulation Development

Receive prototype formulations in 4-8 weeks

 

Simple Manufacturing

One-step manufacturing with standard equipment

Safe Excipients

Only FDA-approved inactive ingredients are used 

Our technology

Learn more about our formulation platforms

 

Learn more

Our services

Learn more about our services

 

Learn more

This website uses cookies to track the usage of it.

More info